Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years immune therapy has moved from later stage therapy in mccRCC to first line therapy. Additionally, combination therapy appears to be more effective than single-agent immune therapy in this disease setting. This presentation will compare the combination first-line therapies for mccRCC. Also we will discuss the current role for immune therapy in mPC and the ideal patient to treat with immune therapy. Finally we will discuss possible future combination immune therapies for mPC.
1. Understand the optimal first-line therapies for patients with metastatic clear cell renal carcinoma
2. Understand the impact of cancer vaccines in the treatment of metastatic testosterone suppression resistant prostate cancer (mCRPC)
3. Define the optimal patient likely to benefit from Provenge